MedPath

Kelonia Therapeutics, Inc.

Kelonia Therapeutics, Inc. logo
🇺🇸United States
Ownership
Holding
Employees
11
Market Cap
-
Website
http://keloniatx.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (100.0%)

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Not Applicable
Recruiting
Conditions
Multiple Myeloma in Relapse
Myeloma Multiple
Multiple Myeloma Progression
Neoplasms by Histologic Type
Neoplasm
Hemostatic Disorders
Vascular Disorder
Paraproteinemias
Blood Protein Disorders
Hematologic Disease and Disorders
Interventions
First Posted Date
2025-07-20
Last Posted Date
2025-07-25
Lead Sponsor
Kelonia Therapeutics, Inc.
Target Recruit Count
40
Registration Number
NCT07075185
Locations
🇦🇺

The Royal Prince Alfred, Camperdown, New South Wales, Australia

🇦🇺

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

🇦🇺

The Alfred Paula Fox Melanoma and Cancer Centre, Melbourne, Victoria, Australia

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.